Overview

Outpatient Discharge Therapy With Saxagliptin+MetforminXR vs GlipizideXL for Type 2 Diabetes With Severe Hyperglycemia

Status:
Unknown status

Trial end date:
2012-12-01

Target enrollment:

Participant gender:

Summary

Saxagliptin + Metformin XR (S+M) will be effective in stabilizing blood glucose (BG) levels in patients with newly diagnosed type 2 diabetes (T2DM) with severe hyperglycemia (BG levels 300 to 450 mg/dl) and glucose toxicity and with no criteria for inpatient admission or occurrence of severe hypoglycemia compared to glipizide XL. The study may provide preliminary evidence to support the role of S+M as a bridging, stabilizing and safe therapy in patients with severe hyperglycemia

Phase:

Phase 4

Details

Lead Sponsor:

John H. Stroger Hospital

Collaborator:

Bristol-Myers Squibb

Treatments:

Glipizide
Metformin
Saxagliptin